Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenous Acid + Chemotherapy in Refractory TNBC
NCT06678048Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Oct 2024
- Primary completion
- Apr 2026
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of arsenous acid in triple-negative breast cancer (TNBC), sponsored by Sun Yat-sen University. Started Oct 2024; status: recruiting.
02
Drugs
arsenous acid
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06678048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06678048.